Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms

Dennyson Leandro M. Fonseca, Maj Jäpel, Michael Adu Gyamfi, Igor Salerno Filgueiras, Gabriela Crispim Baiochi, Yuri Ostrinski, Gilad Halpert, Yael Bublil Lavi, Elroy Vojdani, Thayna Silva-Sousa, Júlia Nakanishi Usuda, Juan Carlo Santos E Silva, Paula P. Freire, Adriel Leal Nóbile, Anny Silva Adri, Pedro Marçal Barcelos, Yohan Lucas Gonçalves Corrêa, Fernando Yuri Nery do Vale, Letícia Oliveira Lopes, Solveig Lea SchmidtXiaoqing Wang, Carl Vahldieck, Benedikt Fels, Lena F. Schimke, Gustavo Cabral-Miranda, Mario Hiroyuki Hirata, Taj Ali AKhan, Yen Rei A. Yu, Rodrigo Js Dalmolin, Howard Amital, Aristo Vojdani, Haroldo Dutra Dias, Helder Nakaya, Hans D. Ochs, Jonathan I. Silverberg, Jason Zimmerman, Israel Zyskind, Avi Z. Rosenberg, Kai Schulze-Forster, Harald Heidecke, Rusan Catar, Guido Moll, Alexander Hackel, Kristina Kusche-Vihrog, Yehuda Shoenfeld, Gabriela Riemekasten, Reza Akbarzadeh, Alexandre H.C. Marques, Otavio Cabral-Marques

Research output: Contribution to journalArticlepeer-review

Abstract

Coronavirus disease 2019 (COVID-19) presents a wide spectrum of symptoms, the causes of which remain poorly understood. This study explored the associations between autoantibodies (AABs), particularly those targeting G protein-coupled receptors (GPCRs) and renin‒angiotensin system (RAS) molecules, and the clinical manifestations of COVID-19. Using a cross-sectional analysis of 244 individuals, we applied multivariate analysis of variance, principal component analysis, and multinomial regression to examine the relationships between AAB levels and key symptoms. Significant correlations were identified between specific AABs and symptoms such as fever, muscle aches, anosmia, and dysgeusia. Notably, anti-AGTR1 antibodies, which contribute to endothelial glycocalyx (eGC) degradation, a process reversed by losartan, have emerged as strong predictors of core symptoms. AAB levels increased with symptom accumulation, peaking in patients exhibiting all four key symptoms. These findings highlight the role of AABs, particularly anti-AGTR1 antibodies, in determining symptom severity and suggest their involvement in the pathophysiology of COVID-19, including vascular complications.

Original languageEnglish
Pages (from-to)7
Number of pages1
Journalnpj Systems Biology and Applications
Volume11
Issue number1
DOIs
StatePublished - 13 Jan 2025
Externally publishedYes

ASJC Scopus subject areas

  • Modeling and Simulation
  • General Biochemistry, Genetics and Molecular Biology
  • Drug Discovery
  • Computer Science Applications
  • Applied Mathematics

Fingerprint

Dive into the research topics of 'Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms'. Together they form a unique fingerprint.

Cite this